The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Sun, Dingqi ^a   Lu, Jiaju ^a   Ding, Kejia ^a   Bi, Dongbin ^a   Niu, Zhihong ^a   Cao, Qingwei ^a   Zhang, Jie ^a   Ding, Sentai ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Eg5; Prognosis; Recurrence; Renal cell carcinoma

Indexed keywords

KINESIN; PROTEIN EG5; UNCLASSIFIED DRUG; KIF11 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY SURGERY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TUMOR VOLUME; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; KINESIN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880618527     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0476-0     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
2. Tulia BM, Whitemore WF Jr. Solitary metastasis from renal cell carcinoma. J Urol. 1975;114:836-8.
3. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193-205.
4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477-90.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
6. Lee HJ, Liang ZL, Huang SM, et al. Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma. Oncol Lett. 2012;3:490-6.
7. Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171:2461-6.
8. Dudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005;11:2510-7.
9. Dorević G, Matusan-Ilijas K, Babarović E, et al. Hypoxia inducible factor-1a correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. Clin Cancer Res. 2009;28:40.
10. Kapitein LC, Peterman EJ, Kwok BH, et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature. 2005;435:114-8.
11. Shimizu M, Ishii N, Ogo N, et al. S-trityl-l-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line. Cancer Lett. 2010;298:99-106.
12. Mayer TU, Kapoor TM, Haggarty SJ, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999;286:971-4.
13. Nakai R, Iida S, Takahashi T, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res. 2009;69:3901-9.
14. Ding S, Nishizawa K, Kobayashi T, et al. A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor. J Urol. 2010;184:1175-81.
15. Tao W, South VJ, Diehl RE, et al. An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol. 2007;27:689-98.
16. Ding S, Xing N, Lu J, et al. Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma. Int J Urol. 2011;18:432-8.
17. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer Verlag; 2009.
18. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-63.
19. Buzaid AC, Todd MB. Therapeutic options in renal cell carcinoma. Semin Oncol. 1989;16:12-6.
20. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477-90.
21. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084-96.
22. Girgin C, Tarhan H, Hekimgil M, et al. P53 mutations and other prognostic factors of renal cell carcinoma. Urol Int. 2001;66:78-83.
23. Saijo T, Ishii G, Ochiai A, et al. Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Lung Cancer. 2006;54:217-25.
24. Hansen GM, Justice MJ. Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia. Oncogene. 1999;18:6531-9.
25. Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem. 2005;280:11569-77.
26. Lee CW, Bélanger K, Rao SC, et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2008;26:249-55.
27. Tang PA, Siu LL, Chen EX, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2008;26:257-64.
28. Liu M, Wang X, Yang Y, et al. Ectopic expression of the microtubule-dependent motor protein Eg5 promotes pancreatic tumourigenesis. J Pahtol. 2010;221:221-8.
29. Langner C, von Wasielewski R, Ratschek M, et al. Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch. 2004;445:631-6.
30. Haitel A, Wiener HG, Neudert B, et al. Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology. 2001;58:477-81.